6 recruiting, 3 completed, 1 terminated. 8 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Recruiting 4, Completed 3, Terminated 1 |
| Phase 2 | 2 | Recruiting 2 |
| Phase 3 | 1 | Recruiting 1 |
Follow Nurix Therapeutics, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies NX-5948, venetoclax, rituximab - B-cell Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Nurix Therapeutics, Inc. | 150 | 2026-09-30 | 2026-10-22 |
| Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL NX-5948, Pirtobrutinib - B-cell Lymphoma, Chronic Lymphocytic Leukemia | Phase 3 | Recruiting | Nurix Therapeutics, Inc. | 620 | 2026-08-03 | 2026-08-31 |
| A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) NX-5948 - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 2 | Recruiting | Nurix Therapeutics, Inc. | 100 | 2025-10-15 | 2026-09-17 |
| A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers NX-5948, Esomeprazole, Placebo - Healthy Volunteer | Phase 1 | Completed | Nurix Therapeutics, Inc. | 223 | 2024-11-30 | 2026-07-28 |
| Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948 NX-5948 - Healthy Volunteer | Phase 1 | Completed | Nurix Therapeutics, Inc. | 8 | 2024-11-01 | 2025-03-12 |
| A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects IP, Matching Placebo - Healthy Volunteers | Phase 1 | Completed | Nurix Therapeutics, Inc. | 32 | 2024-08-20 | 2025-03-14 |
| A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies NX-5948 - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 1 | Recruiting | Nurix Therapeutics, Inc. | 572 | 2022-04-13 | 2026-07-02 |
| A Study of DeTIL-0255 in Adults With Advanced Malignancies Drug Product De-TIL-0255 - Platinum-resistant Ovarian Cancer, Endometrial Cancer | Phase 1 | Terminated | Nurix Therapeutics, Inc. | 5 | 2021-12-22 | 2024-05-03 |
| A Study of NX-1607 in Adults With Advanced Malignancies NX-1607, Paclitaxel - Ovarian Cancer, Epithelial, Gastric Cancer | Phase 1 | Recruiting | Nurix Therapeutics, Inc. | 345 | 2021-09-29 | 2025-09-09 |
| A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies NX-2127 - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 1 | Recruiting | Nurix Therapeutics, Inc. | 248 | 2021-05-05 | 2026-03-20 |
Leukemia, Lymphocytic, Chronic, B-Cell (5) · Lymphoma (3) · Lymphoma, Large B-Cell, Diffuse (3) · Lymphoma, B-Cell (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Follicular (2) · Lymphoma, Mantle-Cell (2) · Uterine Cervical Neoplasms (2) · Waldenstrom Macroglobulinemia (2) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Transitional Cell (1) · Endometrial Neoplasms (1) · Mesothelioma, Malignant (1) · Neoplasm Metastasis (1)
Digoxin (1) · Esomeprazole (1) · Famotidine (1) · Midazolam (1) · Paclitaxel (1) · Quinidine (1) · Rituximab (1) · Rosuvastatin Calcium (1) · obinutuzumab (1) · pirtobrutinib (1) · venetoclax (1)
United States (10) · United Kingdom (3) · France (2) · Italy (2) · Poland (2) · Netherlands (1) · Spain (1) · Switzerland (1)
Sarah Injac, MD PhD (2) · Linda Neuman, MD (1) · Paula O'Connor (1)
2023 (1), 2025 (1)